GSK plc announced that its executives, including CEO Emma Walmsley, acquired ordinary shares on January 16, 2024, following dividend reinvestments from January 11, 2024, with prices at £15.8399 per share. Key transactions include Walmsley purchasing 0.005 shares, and Chief Commercial Officer Luke Miels buying 5,152.032 shares.